DFCM
SPRY icon

Dark Forest Capital Management’s ARS Pharmaceuticals SPRY Stock Holding History

Dark Forest Capital Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-50,940
Closed -$512K – 1316
2025
Q3 		$512K Buy
+50,940
New +$731K 0.02% 920
2025
Q2 		– Sell
-56,553
Closed -$711K – 1492
2025
Q1 		$711K Buy
+56,553
New +$680K 0.03% 822
2021
Q3 		– Sell
-18
Closed -$1K – 1526
2021
Q2 		$1K Buy
+18
New +$577 ﹤0.01% 793

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Dark Forest Capital Management's SPRY Position: Q4 2025 in Review

Dark Forest Capital Management sold out of ARS Pharmaceuticals (SPRY) in Q4 2025, closing a stake of 50,940 shares — an estimated $512K sold.

Dark Forest Capital Management first reported a position in SPRY in Q2 2021 and held it in 3 quarters. The position peaked at $711K in Q1 2025. 189 funds tracked by Wall St. Rank hold SPRY as of Q4 2025.

  • Dark Forest Capital Management reported no remaining ARS Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Dark Forest Capital Management sold 50,940 ARS Pharmaceuticals shares in Q4 2025, an estimated $512K.
  • Dark Forest Capital Management first reported a position in ARS Pharmaceuticals in Q2 2021 and held it in 3 quarters.
  • Dark Forest Capital Management's ARS Pharmaceuticals position peaked at $711K in Q1 2025.
  • 189 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q4 2025.

Based on Dark Forest Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.